Abeona Therapeutics Inc. (ABEO) stock
ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/3039% below fair value
$2.42+0.13 (+5.68%)
Close on Nov 13, 2026Market cap $138.39MP/E –Yield –
Abeona Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Abeona Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$69.65M. For fiscal 2025 it was -$86.90M. The highest annual figure on record is -$3.12M in fiscal 2014.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$86.90M | – |
| FY2024 | Dec 31, 2024 | -$62.21M | – |
| FY2023 | Dec 31, 2023 | -$44.85M | – |
| FY2022 | Dec 31, 2022 | -$47.82M | – |
| FY2021 | Dec 31, 2021 | -$86.59M | – |
| FY2020 | Dec 31, 2020 | -$76.83M | – |
| FY2019 | Dec 31, 2019 | -$69.27M | – |
| FY2018 | Dec 31, 2018 | -$55.81M | – |
| FY2017 | Dec 31, 2017 | -$27.10M | – |
| FY2016 | Dec 31, 2016 | -$23.06M | – |
| FY2015 | Dec 31, 2015 | -$18.00M | – |
| FY2014 | Dec 31, 2014 | -$3.12M | – |
| FY2013 | Dec 31, 2013 | -$3.80M | – |
| FY2012 | Dec 31, 2012 | -$3.90M | – |
| FY2011 | Dec 31, 2011 | -$7.64M | – |
| FY2010 | Dec 31, 2010 | -$7.52M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$12.30M | – |
| Q2 FY2026 | Jun 30, 2026 | -$12.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.34M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.05M | – |
| Q3 FY2025 | Sep 30, 2025 | -$23.42M | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.19M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.19M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.13M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.85M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.84M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.72M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.95M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.38M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$19.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$45.85M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.07M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.92M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.78M | – |
| Q4 FY2020 | Dec 31, 2020 | -$13.64M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.65M | – |
| Q1 FY2020 | Mar 31, 2020 | -$46.15M | – |
| Q4 FY2019 | Dec 31, 2019 | -$14.34M | – |
| Q3 FY2019 | Sep 30, 2019 | -$15.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$21.92M | – |
| Q1 FY2019 | Mar 31, 2019 | -$17.40M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.62M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.41M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.27M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.51M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.60M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.22M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.23M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.03M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.58M | – |
See a number that looks wrong?